TREATMENTS &
RESEARCH

Search the
latest
treatment
information
here.

Dr. Huntley's
Diagnosis
Checklist

Have a symptom?
See what questions
a doctor would ask.

Diseases » Adrenocortical carcinoma » Clinical Trials

Clinical Trials for Adrenocortical carcinoma

Clinical trials are research studies conducted in an effort to improve overall patient health and care. Each trial involves running supervised tests to determine the effectiveness and safety of new drugs, procedures and/or devices with the aim of answering scientific questions about a disease or condition. Risks and side-effects are also evaluated during these trials with results ranging from being unpleasant, with side effects such as headaches, to more serious or even life-threatening risks. A clinical trial may be separated into phases, or steps, with each step designed to answer a separate research question. This maybe reflected in the trial name.

A brief description of each phase:

Phase I: Usually designed to evaluate safety, determine a safe dosage range, and identify side effects on a small group of patients.
Phase II: If Phase I is successful, the trial is then repeated with a larger group to further evaluate its effect and safety.
Phase III: Trials are conducted on an ever larger group and are compared with the best current treatment while gathering more information on effect and safety.
Phase IV: These studies monitor long-term side effects after the treatment has been marketed.

Clinical Trials data for Adrenocortical carcinoma is grouped into the following categories:-

View by trial name

View by drugs used in Adrenocortical carcinoma clinical trials

Clinical Trials by trial name

The format for each of the following is:

The name of the trial,
followed by whether the trial is recruiting patients,
- The trial may not have started and not yet recruiting, or the trial may have started and do not need any more recruitements, or the trial may be completed.
- Note**: Please follow the link to determine the current trial status.
followed by a list of drug/s, if any, used in the trial

ClinicalTrials.gov has listed the following trials for Adrenocortical carcinoma:

Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - hydrocortisone,suramin
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor - This study is not yet open for patient recruitment (Current: 23 Nov 2006) - cisplatin,doxorubicin hydrochloride,etoposide,filgrastim,mitotane,pegfilgrastim
Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide Plus Surgery in Treating Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer - This study is currently recruiting patients (Current: 23 Nov 2006) - doxorubicin hydrochloride,etoposide,mitotane,tariquidar,vincristine
Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer - This study is currently recruiting patients (Current: 23 Nov 2006) - antineoplaston A10,antineoplaston AS2-1
Trial With Taxotere and Cisplatin in Non-Operable Adrenocortical Carcinoma - This study is currently recruiting patients (Current: 23 Nov 2006) - cisplatin,taxotere
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection - This study has been completed (Current: 23 Nov 2006)
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) - This study is currently recruiting patients (Current: 23 Nov 2006) - Iressa (ZD1839)
Penclomedine in Treating Patients With Solid Tumors or Lymphoma - This study has been completed (Current: 23 Nov 2006) - penclomedine
Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - ecteinascidin 743
Combination Chemotherapy in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - fluorouracil,leucovorin calcium,topotecan
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - interferon alfa,interleukin-12
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - amifostine,carboplatin,cyclophosphamide,sargramostim
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of the HER2/Neu Protein - This study is no longer recruiting patients (Current: 23 Nov 2006) - interleukin-12,trastuzumab
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer - This study has been completed (Current: 23 Nov 2006) - R115777,R115777/trastuzumab,trastuzumab
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer - This study has been completed (Current: 23 Nov 2006) - decitabine
Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors - This study has been completed (Current: 23 Nov 2006) - irinotecan,LY231514
Combination Chemotherapy in Treating Patients With Advanced Cancer - This study is no longer recruiting patients (Current: 23 Nov 2006) - fluorouracil,leucovorin calcium,SCH 66336
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - L-778,123
Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas - This study is no longer recruiting patients (Current: 23 Nov 2006) - L-778,123,L-778,123/paclitaxel,paclitaxel
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma - This study is no longer recruiting patients (Current: 23 Nov 2006) - MS-275
Sorafenib and Bevacizumab in Treating Patients With Refractory, Metastatic, or Unresectable Solid Tumors - This study has been suspended (Current: 23 Nov 2006) - bevacizumab,sorafenib tosylate
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) - This study is currently recruiting patients (Current: 23 Nov 2006) - Etoposide,Doxorubicin,Cisplatin,Streptozotocin,Mitotane
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors - This study has been completed (Current: 23 Nov 2006) - cisplatin,doxorubicin,tamoxifen
Peripheral Stem Cell Transplant and White Blood Cell Transfusions in Treating Patients With Refractory Metastatic Solid Tumors - This study is currently recruiting patients (Current: 23 Nov 2006) - allogeneic lymphocytes,anti-thymocyte globulin,cyclophosphamide,cyclosporine,fludarabine phosphate
Study of Adrenal Gland Tumors - This study is currently recruiting patients (Current: 23 Nov 2006)
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment - This study is currently recruiting patients (Current: 23 Nov 2006) - oxaliplatin
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent - This study is currently recruiting patients (Current: 23 Nov 2006) - ADH -1 (Exherin™)

Drugs used in Clinical Trials for Adrenocortical carcinoma

The format for each of the following is:

The drug,
followed by the name of the trial,
followed by whether the trial is recruiting patients,
- The trial may not have started and not yet recruiting, or the trial may have started and do not need any more recruitements, or the trial may be completed.
- Note**: Please follow the link to determine the current trial status.

ClinicalTrials.gov has listed the following drugs in trials for Adrenocortical carcinoma: